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Abstract: Angiogenesis is an important issue in cancer research and opioids are often used to 
treat pain in cancer patients. Therefore it is important to know if the use of opioids is associ-
ated with an aberrant stimulation of tumor growth triggered by the stimulation of angiogenesis 
in cancer patients. Some studies in the literature have suggested the presence of the μ3 opioid 
receptor, known as the receptor for many opioids, on endothelial cells, which are key players in 
the process of angiogenesis. In this study we used endothelial cells known to express the μ3 opioid 
receptor (MOR3), to evaluate the effects of morphine on angiogenesis. We ﬁ  rst investigated the 
effect of morphine on the proliferation of endothelial cells. We showed that morphine is able 
to stimulate vascular endothelial cell proliferation in vitro. This effect of morphine is mediated 
by the mitogen-activated protein kinase (MAPK) pathway as pre-treatment with PD98059 
inhibited this excessive proliferation. Because previous studies indicated nitric oxide (NO) as 
a downstream messenger we investigated the role of NO in the aberrant proliferation of endo-
thelial cells. Our data could not conﬁ  rm these ﬁ  ndings using intracellular NO measurements 
and quantitative ﬂ  uorescence microscopy. The potential use and pitfalls of opioids in cancer 
patients is discussed in light of these negative ﬁ  ndings.
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Introduction
Angiogenesis, the sprouting of new blood vessels, is fundamental for new organ 
development and for differentiation during embryogenesis, wound healing, and repro-
ductive functions in adults. The vascular system is essential for supplying tissues with 
oxygen and nutrients and for the removal of metabolic end products. Angiogenesis is 
also an important factor in some pathological conditions, such as rheumatoid arthritis, 
proliferative retinopathies, and psoriasis, as well as tumor growth and metastasis. This 
complex process, during which endothelial cells play an important role, is tightly 
regulated by pro- and anti-angiogenic growth factors. Endothelial cells line the intimal 
surface of blood vessels, the barrier between blood and tissue. Angiogenesis proceeds 
in several steps including degradation of the basement membrane, migration of endo-
thelial cells towards an angiogenic stimulus, proliferation of endothelial cells, lumen 
formation and the formation of a new extracellular matrix. Because of the prime role 
of endothelial cells during blood vessel formation, these cells are important targets 
in cancer research.1–3
For the treatment of pain in cancer patients, opioids are often used and morphine 
is an important example of such a pain-relieving drug. Opioid alkaloids, as well as 
endogenous opioid peptides, exert their analgesic effects on target tissues through 
the interaction with speciﬁ  c cell surface receptors including the δ-, κ-, and μ-opioid 
receptors. The μ-opioid receptor (MOR) serves as the principle physiological target 
for most, clinically important, opioid analgesics including morphine and fentanyl.4 Journal of Pain Research 2009:2 60
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The opioid receptors are mainly localized in the nervous 
system, but it is already shown that endothelial cells also 
express a subtype on their cell surface. The μ3 opiate recep-
tor is a high afﬁ  nity, saturable opiate-binding site presumed 
to mediate morphine effects. So it is already demonstrated 
with endothelial cultures, that morphine affects endothelial 
cells possibly leading to vasodilatation.5 A clear mechanism 
for this effect was not put forward.
The μ3-opioid receptor is a G-protein coupled receptor 
(GPCR) that, after ligand binding, activates downstream 
G-proteins.4 This active G-protein can interact with other 
effector proteins and potentially stimulate different sig-
nal pathways, for example the mitogen-activated protein 
kinase (MAPK)-pathway. MAP-kinases are important 
intracellular components downstream of receptors and 
sensors and are able to split an extracellular stimulus to an 
intracellular response. This pathway exists in all eukary-
otes and controls fundamental cellular processes such as 
proliferation, differentiation, survival and apoptosis. The 
basic arrangement includes a sensor (receptor) working 
upstream of a core module consisting of three kinases: 
a MAPK kinase kinase (MAPKKK) that phosphorylates and 
activates a MAPK kinase (MAPKK), which in turn activates 
MAPK.6 But also many receptors tyrosine kinases have been 
shown to activate the MAPK pathway.7 Previous studies 
have proposed nitric oxide (NO) as being the downstream 
mediator of the morphine effects. NO is a ubiquitously 
expressed mediator of intracellular signaling originating 
from various sources. We hypothesized that morphine may 
induce cell proliferation by activating MAPK via NO in the 
endothelium. To substantiate the above hypothesis, we used 
proliferation assays, western blot analysis and quantitative 
ﬂ  uorescence microscopy.
Materials and methods
Cell culture
Human umbilical arterial endothelial cells (HUAEC) 
(Cambrex Bio Science, Baltimore, MD) were maintained in 
EGM – 2MV Bulletkit (Cambrex BioScience), consisting of 
endothelial cell basal medium – 2 and the following growth 
supplements: fetal bovine serum (FBS), hydrocortisone 
(0.2 ml), human ﬁ  broblast growth factor-basic (hFGF-B) 
(2 ml), vascular endothelial growth factor (VEGF) (0.5 ml), 
R3–insulin-like growth factor-1 (R3–IGF-1) (0.5 ml), ascor-
bic acid (0.5 ml), human epidermal growth factor (hEGF) 
(0.5 ml), GA-1000 (0.5 ml). Cells were cultured in T-75 
ﬂ  asks at 37 °C in a 5% CO2 atmosphere and they were split 
1:2 twice a week.
Proliferation assays
HUAEC were plated at a density of 1000 cells/well in a 
96-well plate. Cells were incubated with morphine, VEGF or 
SNAP (S-nitroso-N-acetylpenicillamine) in culture medium 
for three days. When using the inhibitor, cells were pretreated 
for four hours before adding morphine, VEGF, or SNAP.
Proliferation was measured by using the CellTiter - GloTM 
Luminescent Cell Viability Assay (Promega, Madison, WI). 
It is a homogeneous method for determining the number of 
viable cells in a culture based on the quantiﬁ  cation of the 
adenosine triphosphate content, which is proportional to the 
number of metabolically active cells. The luminescent signal, 
produced by the luciferase reaction is measured by a lumi-
nometer with an integration time of one second per well.
Western blot analysis
HUAEC cells were plated in petri-dishes at ± 600,000 cells/
dish in complete culture medium. The next day, cells were 
treated for 30 minutes with morphine or VEGF and were 
then harvested into icecold lysis buffer (50 mM TRIS-HCl, 
2 mM EGTA, 1% SDS and one tablet Complete Protease 
Inhibitor Cocktail [ORIGIN] per 50 ml buffer). The different 
fractions were diluted 1:1 with sample buffer (Invitrogen, 
Carlsbad, CA) and boiled for four minutes. Equal volumes 
of the samples were subjected to gel electrophoresis in a 
10% TRIS-glycine gel (Invitrogen) followed by transfer of 
the proteins to nitrocellulose membranes. Membranes were 
blocked with 0.1% Tween in PBS containing 10% nonfat 
dry milk for 30 minutes at room temperature, incubated 
overnight at 4 °C either with p44/42 MAP Kinase-antibody 
(Cell Signaling, Beverly, MA) at a dilution of 1:100 or with 
phospho-p44/42 MAP-Kinase (Cell Signalling) at a dilu-
tion of 1:500 or with monoclonal anti-actin clone AC-40 
(Sigma-Aldrich, St. Louis, MO) at a dilution of 1:200 and 
washed extensively. They were then incubated either with 
a horseradish peroxidase-conjugated anti-rabbit antibody 
at a dilution of 1:1000 or with a horseradish peroxidase-
conjugated anti-mouse antibody at a dilution of 1:2000 for 
one hour at room temperature before being developed with the 
enhanced chemiluminescent substrate (SuperSignal® West 
Pico Chemiluminescent Substrate; Pierce, Rockford, IL).
NO measurements
For the real-time detection of NO, we used the NO indica-
tor DAF-FM (4-amino-5-methylamino-2’, 7’-difluoros-
cein) Diacetate (Molecular Probes, Eugene, OR), which is 
nonﬂ  uorescent until it reacts with NO to form a ﬂ  uorescent 
benzotriazole. Cells were plated in a 96-well plate with a Journal of Pain Research 2009:2 61
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glass bottom, incubated with the diluted DAF-FM diacetate 
(1 μM) for 30 minutes at 37 °C and washed with buffer 
to remove excess probe. Cells were then incubated for an 
additional 30 minutes at room temperature to allow complete 
de-esteriﬁ  cation of the intracellular probe. The image record-
ing system consists of a Axiovert S135 inverted microscope 
(Zeiss, Oberkochen, Germany) equipped with a motorized 
(x,y)-stage (Märzhauser, Wetzlar, Germany), focus-drive 
and CCD-camera (Photonics, Shizuoka, Japan). Proprietary 
software allows automated focusing, image acquisition, and 
storage for each well. A 96 well plate is put on the stage 
and the user selects the ﬁ  elds containing cells to be imaged 
over time. When all desired ﬁ  elds are selected, images are 
recorded automatically during a preset time. The objects of 
interest were detected in each ﬁ  eld and the ﬂ  uorescence inten-
sity of each object is continuously measured for 20 minutes 
(FITC ﬁ  lter). After minute 5, cells were stimulated with 
morphine or SNAP, a NO-donor (positive control). Each 
experiment was simultaneously performed with a control 
(vehicle alone) to exclude experimental drift in NO release 
unrelated to the study drugs.
Statistical analysis
For the proper analysis, the absolute values of each of the 
proliferation assays and NO measurements were converted 
into relative values, with the respective control condition set 
as 100%. All of the data are expressed as mean ± SEM. The 
data were evaluated with the nonparametric Mann-Whitney 
test using Minitab statistical software (Minitab Inc., State 
College, PA). Differences with the control group were con-
sidered statistically signiﬁ  cant at P  0.05.
Results
Effects of morphine on endothelial 
cell proliferation
To investigate if morphine has proliferative stimulus proper-
ties on endothelial cells, it was compared to VEGF. Prolif-
eration assays were performed in the presence of different 
concentrations of the opioid (10 μM–10 nM), but also in the 
presence of VEGF and SNAP as positive controls. SNAP 
is a NO-donor under physiologic conditions. A signiﬁ  cant 
stimulation of endothelial cell proliferation occurred in the 
range between 1 μM to 10 nM morphine (P  0.01 versus 
control; Figure 1A). An increase in cell density of about 26% 
was measured with morphine 100 nM and an increase of more 
than 30% with VEGF 100 ng/ml. Also the release of NO by 
the NO-donor SNAP 50 μM stimulated the proliferation of 
the HUAEC cells to a similar degree.
Effects of the MAPK-inhibitor PD98059 
on endothelial cell proliferation
To illustrate the role of the MAPK pathway in mediating the 
morphine-induced proliferation, experiments were performed 
in the absence and the presence of the MAPK-inhibitor 
PD98059 (Figure 1B). Under every condition, there was a 
clear inhibition of the endothelial cell proliferation by the 
MAPK-inhibitor PD98059 at 3 μM, but the effect on the 
morphine dose range is larger than the effect on the control 
condition (± 25% decrease versus 12.14% decrease). As 
such, the MAPK – inhibitor PD98059 clearly inhibits the 
morphine – induced HUAEC proliferation.
Effects of morphine on the NO 
production in HUAEC cells
To evaluate the potential role of NO in the stimulation 
of HUAEC proliferation, NO production upon morphine 
addition was measured. A live cell imaging system was 
used to quantify intracellular NO levels at the single cell 
level by measuring the intensity of DAF-FM diacetate, a 
NO-speciﬁ  c ﬂ  uorescent dye. Experiments were done with 
different concentrations of morphine and SNAP as a positive 
control. Only the addition of SNAP 100 μM resulted in an 
increase in ﬂ  uorescent signal intensity which was statisti-
cally signiﬁ  cant and different from the control condition 
(P  0.05; Table 1).
Figure 2 illustrates the data sampling in the live cell 
imaging set-up. With the addition of SNAP 10 μM no 
increase in the ﬂ  uorescence signal was detected (Table 1), 
while 50 μM was able to stimulate the proliferation of 
HUAEC (Figure 1A: 30% increase in proliferation rate as 
compared with control cultures).
Inﬂ  uence of morphine on the activation 
of MAPK
Based on the results of the cell proliferation experiments 
with the MAPK-inhibitor, there was already an indication 
for a role for MAPK as mediator of the morphine induced 
HUAEC cell proliferation. To further substantiate this 
observation, the activation of the MAPK pathway was 
studied by western blots. The fraction of phosphorylated 
enzyme is indicative for the level of activation of the second 
messenger cascade and illustrates the effects of morphine 
on the MAPK activation cascade. An increased signal was 
observed with morphine and VEGF as demonstrated via 
detection with an antibody against the phosphorylated 
enzyme. Especially the highest morphine concentration Journal of Pain Research 2009:2 62
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(10 μM) indicated a clear activation of MAPK (Figure 3 
panel A top).
Inﬂ  uence of PD98059 on the activation 
of MAPK
As control for the use of the MAPK-inhibitor PD98059 in 
the proliferation assays, the effect of this inhibitor was also 
studied by western blotting. PD98059 inhibits the second 
enzyme (= MAPKK) in the cascade and as such inhibits 
the phosphorylation/activation of the next enzyme, namely 
the important MAPK. Treating HUAEC for 30 minutes 
with morphine or VEGF clearly induced the phosphoryla-
tion/activation of the MAPK enzyme (Figure 3, panel A). If 
we compare the samples without inhibitor with those with 
inhibitor (Figure 3, panel A versus panel B), a decrease of the 
signal was seen with the phospho-MAPK antibody (Figure 3, 
panel B at the top). Pre-treatment with 3 μM PD98059 
during four hours inhibited the morphine-induced MAPK 
phosphorylation. When using the total MAPK antibody, no 
decrease was observed (Figure 3, panel B in the middle). 
As a control a similar experiment was performed using an 
anti-actin antibody (Figure 3, panel B bottom). The signal 
was equal for all samples and indicative for the speciﬁ  city 
of the MAPK-inhibitor assay.
Discussion
The potential effect of morphine on the proliferation of 
endothelial cells is extremely important merely because 
morphine is often used to treat pain all over the world without 
having well documented the effects on nonneuronal tissue. 
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Figure 1 Morphine,   VEGF,  and SNAP 10 μM stimulate HUAEC proliferation after three days of incubation A). The MAPK-inhibitor PD98059 reduces the proliferation capacity 
of HUAEC cells after three days of incubation B).
Notes: Mann–Whitney U Test was used for statistical analyses;  A) *P  0.01; **P  0.005, compared with control;  B) #P < 0.05; §P  0.005, conditions with PD98059 compared 
with conditions without PD98059. Each experiment was repeated at least four times in triplicate (n = 12), except PD/VEGF 100 ng/ml and PD/SNAP 50 and 10 μM, which 
were run twice (n = 8). Each value indicates mean; bars ± SEM.
Abbreviations: HUAEC, human umbilical endothelial cells; MAPK, mitogen-activated protein kinases; SNAP, S-nitroso-N-acetylpenicillamine; VEGF, vascular endothelical 
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Morphine induces pain relief by blocking the transmission 
of the sensory system. At ﬁ  rst the effects of the opioids, 
especially on analgesic and anti-nociceptive properties, were 
examined. Later, a number of experiments have demonstrated 
that morphine modulates the activity of a variety of cell 
types, among them endothelial cells. Therefore, the interest in 
studies on the effects of opiates outside of the nervous system 
increased.5,8 For example, studies on the effects of morphine 
on tumor growth were performed.9 After all, angiogenesis is 
often associated with the pathogenesis of tumor progression 
and metastasis. Despite the widespread use of opioids to 
treat pain in patients with cancer, little is known about the 
effects of these drugs on vascular endothelium, a key player 
in angiogenesis, and hence tumor growth.
Angiogenesis is a complex process regulated by anti- and 
pro-angiogenic factors. One of these factors speciﬁ  c for the 
endothelium is VEGF. In this study, we compared the opiate 
morphine with the positive control VEGF. The biological 
effects of both are mediated by two different receptors. 
Morphine acts on the μ-opioid receptor (GPCR-type), while 
VEGF acts on tyrosine kinase receptors, which are expressed 
mainly on the vascular endothelium.5,10
By using the proliferation assays, we were able to illus-
trate an increased cell number after treatment with morphine. 
The effects of morphine approximate the mitogenic and 
pro-survival activities of VEGF. Morphine induced a nice 
dose-dependent effect between 10 μM and 10 nM. Morphine 
is used clinically in doses of 10–2450 mg/day, resulting 
in serum concentrations that are between 2 nM to 3.5 μM.9 
We found a signiﬁ  cant proliferative stimulus with morphine 
in the range of 1 μM to 10 nM (P  0.05 versus control). 
Thus, at clinically relevant concentrations morphine stimu-
lates endothelial cell proliferation.
The association of the tyrosine kinase receptor with down-
stream activation of the MAPK pathway is common knowl-
edge and the fact that VEGF has an effect on endothelial cells 
through the MAPK pathway was shown.10,11 Besides this, it is 
also known that the activation of the MAPK-cascade can be the 
consequence of the interaction between a GPCR, like MOR, 
and its ligand, in our case morphine.4,12 This signaling pathway 
is one of the most important cascades that convert an extracel-
lullar signal into an intracellular response. The regulation of 
genes by this way regulates biological processes among which 
proliferation.6 Hence, we investigate the importance of MAPK 
within the morphine stimulus. Dissection of the intracellular 
pathway giving rise to the effect and possible side-effects is after 
all important for therapeutic applications. First, we checked 
the involvement of the MAPK-cascade by using an inhibitor, 
PD98059, which works particularly on the second enzyme. In 
this way, the ﬁ  nal enzyme will not be activated and not be able 
to regulate gene expression in the nucleus. The results of the 
proliferation experiments with and without inhibitor PD98059 
in VEGF- and morphine-treated cells illustrated a decrease in 
cell number of 25% and 13% after pretreatment, respectively. 
This underlines the role of the MAPK-pathway in the VEGF- 
and morphine-induced proliferative stimulus.
We also looked at the activation of the MAPK pathway 
by using western blot analysis. Both VEGF and morphine 
10 μM induced a signiﬁ  cant increase in phosphorylated 
MAPK when compared to the controls. This indicates 
an activation stimulus by both factors on the MAPK-
cascade. It is striking that, in the proliferation experiments, 
a maximal stimulus was seen with morphine 100 nM, while 
the activation of MAPK was the strongest with morphine 
10 μM. This can point to differences in exposure time; only 
30 minutes for the western blot experiments while the prolif-
eration experiments were quantiﬁ  ed after chronic exposures. 
Table 1 NO quantification: overview of the fluorescence-
measurements per condition per phase. NO levels were measured 
by quantitative ﬂ  uorescence microscopy in HUAEC cells exposed 
to buffer, SNAP (100–10 μM) or morphine (10 μM–10 nM). Cells 
were loaded with DAF-FM diacetate (1 μM) for 30 minutes before 
stimulation. Data are expressed as mean relative intensity ± SEM, with 
the measurements in phase 1 (= before addition) set as 100%
Condition REL. Intensity + SEM 
(P-value)
N
Control phase 1
phase 2
phase 3
100.00 + 0.00  (/)
99.16 + 0.68  (/)
99.89 + 1.39  (/)
19
SNAP 
100 microM
phase 1
phase 2
phase 3
100.00 + 0.00  (/)
169.71 + 47.23 (p  = 0.0098)
273.78 + 102.44  (p = 0.0129)
3
SNAP 
10 microM
phase 1
phase 2
phase 3
100.00 + 0.00  (/)
96.65 + 0.52  (p = 0.3085)
94.44 + 0.87  (p = 0.0823)
2
Morphine 
10 microM
phase 1
phase 2
phase 3
100.00 + 0.00  (/)
99.68 + 1.26  (p = 0.6332)
102.21 + 3.14 (p  = 0.6332)
6
Morphine 
1 microM
phase 1
phase 2
phase 3
100.00 + 0.00  (/)
103.58 + 3.04  (p = 0.1039)
103.70 + 3.47  (p = 0.1513)
3
Morphine 
0.1 microM
phase 1
phase 2
phase 3
100.00 + 0.00  (/)
99.78 + 0.60  (p = 0.3892)
100.51 + 1.11 (p  = 0.5030)
3
Morphine 
0.01 microM
phase 1
phase 2
phase 3
100.00 + 0.00  (/)
97.99 + 1.30  (p = 0.8574)
98.06 + 1.26  (p = 0.6750)
2
Abbreviations: DAF-FM, 4-amino-5-methylamino-2’, 7’-diﬂ  uoroscein; HUAEC, human 
umbilical endothelial cells; No, nitric oxide; SNAP, S-nitroso-N-acetylpenicillamine.Journal of Pain Research 2009:2 64
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We mainly focused on the proliferation of endothelial 
cells, but the MAPK cascade can also be involved in other 
biological processes, like differentiation and apoptosis.13,14 
Besides this, the phenomenon of ‘desensitization’ can also 
contribute to this fact. It is known that a continuous stimu-
lation of the GPCR can lead to a decrease in response or 
brieﬂ  y, “desensitization”.15,16 In our study of the activation 
of the MAPK pathway, we observed the highest signal with 
morphine 10 μM.
Also the speciﬁ  city of the MAPK pathway was shown by 
the use of the inhibitor PD98059 and conﬁ  rmed by western 
blot. We showed that the inhibitor was able to inhibit the 
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Figure 3 A) Effect of morphine on the activation of MAPK. Treatment during 30 minutes with morphine or VEGF induced the phosphorylation/activation of the MAPK enzyme. 
B) Effect of the MAPK-inhibitor PD98059 on the activation of MAPK. Pretreatment with 3 μM PD98059 during four hours inhibited the morphine-induced MAPK phosphorylation; 
no changes in the total MAPK and actin signal were seen. Control indicates unstimulated cells. The actine label was performed by re-probing the MAPK membranes.
Abbreviations: MAPK, mitogen-activated protein kinases;   VEGF, vascular endothelical growth factor.
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proliferative stimulus of morphine and this provides further 
support for the hypothesis that MAPK plays an essential role 
in the proliferation behavior of the endothelial cells induced 
by morphine.
In studies on the characterization of the cellular pathways 
involved in the VEGF-induced proliferation of endothe-
lial cells, it was already clear that the mitogenic activity 
of VEGF requires the activation of the MAPK cascade. 
Besides this, it was also known that NO/cGMP contributed 
to the pro-angiogenic properties of vascular endothelial 
growth factor in human endothelial cells.7,17 Hence, we 
investigated also the role of NO to the underlying mecha-
nisms of morphine. However, we were not able to detect a 
signiﬁ  cant increase of the amount NO by using quantitative 
ﬂ  uorescence, despite the positive results with the NO donor 
SNAP 100 μM. The only indication for a possible role of 
NO within the morphine-induced proliferative stimulus, 
were the results of the cell density measurements: in our 
experimental approach, we made use of the NO-donor 
SNAP. The increase in cell density induced by SNAP 
50 μM approximated the increased proliferation by VEGF 
(30%). These results only indicate that NO stimulates 
the mitogenic activity of HUAEC cells. The question if 
morphine is able to stimulate the NO production remains 
unclear after our study.
For future experiments, it is important to further clarify 
the role of NO by performing proliferation experiments in 
the presence of a NO inhibitor (eg, L-NAME). The results 
will indicate if NO is required for the morphine-induced 
proliferation.
In a second part, one can compare the effect of morphine 
with other pain-relieving drugs. Because the clinically used 
opioids consist of different chemical classes of compounds 
having different binding and functional proﬁ  les at opiate 
and nonopiate receptors, it is theoretically possible that 
the effects observed with morphine can not be generalized 
to all other agents. By doing the same experiments with 
other agents, one will be able to detect any difference in 
response.
Furthermore, because of the many different phenotypes 
of tumors, some differentiation might be possible and as a 
consequence the effects of various opioids in various cancer 
cell lines should be evaluated before making any generalized 
conclusions.
It is also very important to ﬁ  nd out if the increase in 
proliferation, induced by morphine, can actually give rise 
to a higher pro-angiogenic activity in animal models. It is 
not certain that the increase in cell density of about 26%, 
seen in these in vitro experiments and at high morphine 
concentrations, also results in an increased activity of the 
blood vessel forming process in in vivo experiments. There-
fore, it is necessary to evaluate the effect of morphine on the 
growth and angiogenesis in tumors of different phenotype. 
The evaluation can be done via histological quantiﬁ  cation of 
the tumor vascularisation and via μCT. Our working hypoth-
esis can then be conﬁ  rmed or contradicted by the results of 
those in vivo experiments.
Finally, we can conclude that the pro-angiogenic activity 
of morphine might have implications for the therapeutic use 
of this opiate in a clinical setting if additional and especially 
in vivo experiments conﬁ  rm the present observations. The 
stimulating effect on the proliferation of endothelial cells 
seems a breakthrough in cardiovascular medicine and wound 
healing. In contrast, morphine administration to patients with 
cancer might inadvertently increase angiogenesis, raising 
concerns about the widespread use of this analgesic in those 
patients if the in vitro results can be translated to the in vivo 
situation in humans. It is therefore important to indicate that 
the in vitro data obtained can not simply be generalized to 
humans or to other analgesics.
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